Drug Research
Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON
Targovax ASA, a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, and Agenus, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today...
News
For Stakeholders Bidens Bid To Cut Drug Costs Is A Top Issue
Much of the reaction to President Joe Biden's State of the Union address concentrated on the president's repeated calls for Congress to allow Medicare to negotiate medication prices. That is why bringing prices under control was his top concern, Biden stated...
News
The UK Government Announces £260 Million To Fix Healthcare
The UK government has put forth its intention to invest £260 million in cutting-edge medical research and development, as well as the manufacturing of innovative pharmaceuticals, gadgets, and diagnostics.
Through digital clinical trial services and Trusted Research Environments, the Department of...
News
Untreatable Lung Cancer Patients Get Breakthrough Treatment
The head of the NHS revealed today that a breakthrough targeted medication treating lung cancer would be made accessible to anybody who qualifies, owing to a new drug deal. Sotorasib is a drug that targets a genetic abnormality known...
News
Exclusive license for Croda to commercialise SSI’s CAF vaccine adjuvants
Croda International Plc, which uses smart science to improve lives, announces that it has entered a strategic collaboration with Statens Serum Institut (“SSI”), the leading Danish Governmental life-science research institute.
Croda’s vaccine adjuvant specialists, based in Denmark, will exclusively manufacture,...
News
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its...
Drug Research
IDT Biologika Collaborates with Exothera to Push Forward the Scale-Up of Viral Vaccines
IDT Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses, and Exothera S.A. collaborate to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.















